In a study presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research, researchers sought to identify physicians’ documented granulocyte colony-stimulating factor (G-CSF) use, with a particular focus on filgrastim-sndz since its entry into the marketplace, and identified a slow US uptake for the biosimilar.
To date, there has been little information available about the uptake of filgrastim-sndz in the United States compared to the use of other granulocyte colony-stimulating factor (G-CSF) agents. In a study funded by Envision Market Access Solutions (part of Envision Pharma Group) and presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research, researchers sought to identify physicians’ documented G-CSF use, with a particular focus on the use of filgrastim-sndz since its entry into the marketplace.
The first biosimilar approved in the United States, filgrastim-sndz has been approved for 5 of 6 licensed indications for its reference product (including prophylaxis for and treatment of febrile neutropenia in patients undergoing myelosuppressive chemotherapy) and has been available in the US market since September 2015.
The researchers identified mentions of G-CSF agents in physicians’ records of patient consultation as documented in RealHealthData (a transcription database) for the period of January 1, 2016, to March 31, 2017. The records comprise notes from both office visits and healthcare facility consultations, and included physicians’ intentions to treat with a G-CSF at the time of the consultation, a patient’s G-CSF treatment history, or both.
In addition to tabulating occurrences of the names of 4 G-CSF agents, namely pegfilgrastim (Neulasta), filgrastim (Neupogen), tbo-filgrastim (Granix, Neutroval), and filgrastim-sndz (Zarxio, Zarzio), the researchers also evaluated their prophylactic or curative use against neutropenia.
Per the analysis, physicians made 17,770 mentions of G-CSF agents in 2016:
In the first quarter of 2017, mentions of filgrastim increased to 39.6% of the total number of G-CSF mentions, while mentions of tbo-filgrastim increased to 12.8%. Pegfilgrastim, however, retained the highest share of the total with 47% of mentions.
The data show that, over the full study period, general practitioners were the most frequent providers to mention pegfilgrastim, filgrastim, and tbo-filgrastim (though hospitalists mentioned tbo-filgratim the most often). Data also demonstrate an influence of location: physicians in Pennsylvania mentioned pegfilgrastim the most often, physicians in Texas noted tbo-filgrastim the most often, and providers in Kansas mentioned filgrastim-sndz the most often.
Explaining that their study provides only a proxy of G-CSF use for specific time periods rather than documented treatment patterns for such agents, the authors state that providers’ notes may have been repeated in cases of patient hospitalization over a period of days. Furthermore, the data do not represent all US states, so the study’s findings are not representative of national trends.
Yet the researchers conclude that, among 21,222 records considered in this study, only 140 mentions (0.7% of total mentions) of filgrastim-sndz were noted in the first 18 months of the product’s entry into the US market, and there was no significant increase in the product’s mentions in the first quarter of 2017 when compared with the 2016 period. The researchers also suggest that differences among mentions of filgrastim-sndz and other G-CSF agents across provider types and geographies may indicate differences in formulary listings and clinical treatment patterns across regions. Increased awareness of biosimilars among clinicians and payers, the authors conclude, may be required in order for filgrastim-sndz to see increased uptake.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).